We serve Chemical Name:Methyl 5-(2-bromoacetyl)-2-hydroxybenzoate CAS:36256-45-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Methyl 5-(2-bromoacetyl)-2-hydroxybenzoate
CAS.NO:36256-45-8
Synonyms:methyl 5-(2-bromoacetyl)-2-hydroxybenzoate
Molecular Formula:C10H9BrO4
Molecular Weight:273.08000
HS Code:2918990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:63.60000
Exact Mass:271.96800
LogP:1.75640
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like methyl 5-(2-bromoacetyl)-2-hydroxybenzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 5-(2-bromoacetyl)-2-hydroxybenzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 5-(2-bromoacetyl)-2-hydroxybenzoate Use and application,methyl 5-(2-bromoacetyl)-2-hydroxybenzoate technical grade,usp/ep/jp grade.
Related News: The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. Methyl 5-(2-bromoacetyl)-2-hydroxybenzoate manufacturer The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. Methyl 5-(2-bromoacetyl)-2-hydroxybenzoate supplier Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development. Methyl 5-(2-bromoacetyl)-2-hydroxybenzoate vendor Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion. Methyl 5-(2-bromoacetyl)-2-hydroxybenzoate factory Biogen research chief Alfred Sandrock said the FDA had painstakingly analyzed its clinical trial data over two years before reaching a conclusion.
